Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast 
cancer is caused by aberrant promoter methylation and points to an impact of 
EFEMP1 as molecular biomarker

Sadr-Nabavi, A.; Ramser, J.; Volkmann, J.; Naehrig, J.; Wiesmann, F.; Betz, B.; Hellebrand, H.; Engert, S.; Seitz, S.; Kreutzfeld, R.; Sasaki, T.; Arnold, N.; Schmutzler, R.; Kiechle, M.; Niederacher, D.; Harbeck, N.; Dahl, E.; Meindl, A.

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker

MPS-Authors

/persons/resource/persons78606

Sasaki, T.
Former Research Groups, Max Planck Institute of Biochemistry, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Sadr-Nabavi, A., Ramser, J., Volkmann, J., Naehrig, J., Wiesmann, F., Betz, B., et al. (2009). Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. International Journal of Cancer, 124(7), 1727-1735.

Cite as: https://hdl.handle.net/11858/00-001M-0000-0010-59F7-5

Abstract

There is no abstract available